Characteristics of the study cohorts
| Characteristic . | All patients (n = 4270) n (%) . | Siblings (n = 1827) n (%) . | Unrelated (n = 1447) n (%) . |
|---|---|---|---|
| Recipients genotyped | 3850 (90) | 1676 (92) | 1315 (91) |
| Donors genotyped | 3977 (93) | 1780 (97) | 1338 (92) |
| Patient age at transplantation, y | 43 (0-78) | 45 (0-74) | 44 (0-78) |
| Median | 0 | 0 | 0 |
| Range | 78 | 74 | 78 |
| Donor age, y | 39 | 44 | 33 |
| Median | 19 | 0 | 18 |
| Range | 83 | 83 | 61 |
| Diagnosis | |||
| Acute leukemia | 1761 (41) | 698 (38) | 602 (42) |
| Chronic myeloid leukemia | 1032 (24) | 378 (21) | 342 (24) |
| Myelodysplastic syndrome or myeloproliferative neoplasm | 736 (17) | 297 (16) | 298 (21) |
| Chronic lymphocytic leukemia | 116 (3) | 61 (3) | 43 (3) |
| Malignant lymphoma or multiple myeloma | 625 (15) | 393 (22) | 162 (11) |
| Disease risk* | |||
| Low | 936 (22) | 385 (21) | 314 (22) |
| Intermediate | 1199 (28) | 465 (25) | 460 (32) |
| High | 1881 (44) | 871 (48) | 567 (39) |
| Not classified | 254 (6) | 106 (6) | 106 (7) |
| Donor-recipient gender | |||
| Male to male | 1438 (34) | 563 (31) | 560 (39) |
| Male to female | 953 (22) | 389 (21) | 345 (24) |
| Female to male | 1038 (24) | 500 (27) | 290 (20) |
| Female to female | 839 (20) | 375 (21) | 251 (17) |
| Graft source | |||
| Bone marrow | 2325 (54) | 905 (50) | 701 (48) |
| Mobilized blood cells | 1945 (46) | 922 (50) | 746 (52) |
| Conditioning | |||
| Myeloablative <900 cGy total body irradiation | 1515 (35) | 840 (46) | 456 (32) |
| Myeloablative ≥900 cGy total body irradiation | 2021 (47) | 674 (37) | 664 (46) |
| Nonmyeloablative | 734 (17) | 313 (17) | 327 (23) |
| Initial posttransplant immunosuppression | |||
| Cyclosporine and methotrexate | 2363 (55) | 959 (52) | 684 (47) |
| Cyclosporine and mycophenolate mofetil | 672 (16) | 298 (16) | 291 (20) |
| Tacrolimus and methotrexate | 608 (14) | 183 (10) | 303 (21) |
| Tacrolimus and mycophenolate mofetil | 169 (4) | 74 (4) | 86 (6) |
| Cyclosporine or tacrolimus alone | 218 (5) | 198 (11) | 8 (1) |
| Methotrexate or mycophenolate mofetil alone | 76 (2) | 70 (4) | 3 (<1) |
| Other (cyclophosphamide or antithymocyte globulin) | 164 (4) | 45 (2) | 72 (5) |
| Characteristic . | All patients (n = 4270) n (%) . | Siblings (n = 1827) n (%) . | Unrelated (n = 1447) n (%) . |
|---|---|---|---|
| Recipients genotyped | 3850 (90) | 1676 (92) | 1315 (91) |
| Donors genotyped | 3977 (93) | 1780 (97) | 1338 (92) |
| Patient age at transplantation, y | 43 (0-78) | 45 (0-74) | 44 (0-78) |
| Median | 0 | 0 | 0 |
| Range | 78 | 74 | 78 |
| Donor age, y | 39 | 44 | 33 |
| Median | 19 | 0 | 18 |
| Range | 83 | 83 | 61 |
| Diagnosis | |||
| Acute leukemia | 1761 (41) | 698 (38) | 602 (42) |
| Chronic myeloid leukemia | 1032 (24) | 378 (21) | 342 (24) |
| Myelodysplastic syndrome or myeloproliferative neoplasm | 736 (17) | 297 (16) | 298 (21) |
| Chronic lymphocytic leukemia | 116 (3) | 61 (3) | 43 (3) |
| Malignant lymphoma or multiple myeloma | 625 (15) | 393 (22) | 162 (11) |
| Disease risk* | |||
| Low | 936 (22) | 385 (21) | 314 (22) |
| Intermediate | 1199 (28) | 465 (25) | 460 (32) |
| High | 1881 (44) | 871 (48) | 567 (39) |
| Not classified | 254 (6) | 106 (6) | 106 (7) |
| Donor-recipient gender | |||
| Male to male | 1438 (34) | 563 (31) | 560 (39) |
| Male to female | 953 (22) | 389 (21) | 345 (24) |
| Female to male | 1038 (24) | 500 (27) | 290 (20) |
| Female to female | 839 (20) | 375 (21) | 251 (17) |
| Graft source | |||
| Bone marrow | 2325 (54) | 905 (50) | 701 (48) |
| Mobilized blood cells | 1945 (46) | 922 (50) | 746 (52) |
| Conditioning | |||
| Myeloablative <900 cGy total body irradiation | 1515 (35) | 840 (46) | 456 (32) |
| Myeloablative ≥900 cGy total body irradiation | 2021 (47) | 674 (37) | 664 (46) |
| Nonmyeloablative | 734 (17) | 313 (17) | 327 (23) |
| Initial posttransplant immunosuppression | |||
| Cyclosporine and methotrexate | 2363 (55) | 959 (52) | 684 (47) |
| Cyclosporine and mycophenolate mofetil | 672 (16) | 298 (16) | 291 (20) |
| Tacrolimus and methotrexate | 608 (14) | 183 (10) | 303 (21) |
| Tacrolimus and mycophenolate mofetil | 169 (4) | 74 (4) | 86 (6) |
| Cyclosporine or tacrolimus alone | 218 (5) | 198 (11) | 8 (1) |
| Methotrexate or mycophenolate mofetil alone | 76 (2) | 70 (4) | 3 (<1) |
| Other (cyclophosphamide or antithymocyte globulin) | 164 (4) | 45 (2) | 72 (5) |
Low risk is chronic myeloid leukemia in chronic phase or myelodysplastic syndrome-refractory anemia; intermediate risk, acute leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma in remission; high risk, all others.